Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Profitable Stock to Target This Week and 2 Facing Challenges

2026-01-07
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

The 24% return delivered to IQVIA Holdings' (NYSE:IQV) shareholders actually lagged YoY earnings growth

2026-01-06
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Why IQVIA Holdings Inc. (NYSE:IQV) Looks Like A Quality Company

2026-01-02
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Here's Why You Should Retain IQV Stock in Your Portfolio Now

2025-12-29
IQVIA Holdings shares jump 25.5% in three months as AWS partnership, growing R&DS backlog and buybacks lift its earnings outlook.

Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?

2025-12-28
Let's talk about the popular IQVIA Holdings Inc. ( NYSE:IQV ). The company's shares saw a significant share price rise...

Is IQVIA Holdings Inc. (NYSE:IQV) Trading At A 27% Discount?

2025-12-23
Key Insights The projected fair value for IQVIA Holdings is US$309 based on 2 Stage Free Cash Flow to Equity IQVIA...

Harbor Mid Cap Core ETF Q3 2025 Portfolio Review

2025-12-19
Contributors to Fund performance included DR Horton, Cummins Inc., IQVIA Holdings Inc., CBRE Group, and Ulta Beauty.

Tracking William Nygren's Harris Associates Portfolio - Q3 2025 Update

2025-12-17

Eli Lilly: The Right Long-Term Strategy

2025-12-13
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.

IQVIA: Increasingly Indispensable In Drug Development

2025-12-11
Discover why IQVIA Holdings leads in life sciences data & tech with AI-driven services, strong growth, and up to 30% stock upside.